PUBLICATIONS & ABSTRACTS
- Clinical Validation StudiesPredicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneMarch 2019
Gnant M, Filipits R, Greil H, et al.
Annals of OncologyDevelopment and verification of the PAM50-based Prosigna breast cancer gene signature assayAugust 2015
Wallden B et al.
BMC Medical GenomicsPrediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 RiskOctober 2014
Sestak I, et al.
Journal of Clinical OncologyAnalytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensMarch 2014
Nielsen TO, et al.
BMC CancerComparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine TherapyJuly 2013
Dowsett M. et al.
J Clinical Oncology